#United States #New York #Investor Conferences #oncology #Nuvation Bio

Nuvation Bio to Participate in Key Investor Conferences

Nuvation Bio Inc. (NYSE: NUVB), a prominent player in the oncology sector, is set to participate in multiple investor conferences in May 2026. The participation will include contributions from Dr. David Hung, the company's founder and CEO, and Philippe Sauvage, the Chief Financial Officer. The company aims to address significant challenges in cancer treatment through innovative therapeutic solutions.

Upcoming Conferences

Nuvation Bio will take part in several key events scheduled for May 2026:

• - Bank of America Securities 2026 Healthcare Conference: Scheduled for May 13, 2026, at 8:00 AM PT in Las Vegas, NV, this conference will feature Dr. Hung in a fireside chat discussing current and future directions of oncology therapies.
• - H.C. Wainwright 4th Annual BioConnect Investor Conference: Taking place on May 19, 2026, at 1:30 PM ET at NASDAQ in New York, NY, this conference will also include a fireside chat with insights into Nuvation Bio's innovative pipeline.
• - 2026 RBC Capital Markets Global Healthcare Conference: Dr. Hung will again be featured in a fireside chat on May 20, 2026, at 9:00 AM ET in New York, NY, building on the discussions of the previous week.
• - TD Cowen's 7th Annual Oncology Innovation Summit Insights for ASCO EHA: This virtual fireside chat on May 26, 2026, at 12:00 PM ET will provide an opportunity for a broader audience to engage with Nuvation's leadership about advancements in oncology.

Each of these events will be accessible through webcasts on the Investor Relations section of Nuvation Bio's official website. Recordings will be archived for 90 days post-event for those who miss the live discussions.

Nuvation Bio Overview

Founded in 2018 by David Hung, M.D., who has a rich history in biopharma, Nuvation Bio is dedicated to addressing the most challenging aspects of cancer treatment. Their impressive therapeutic pipeline includes products such as taletrectinib (IBTROZI®), a next-gen ROS1 inhibitor, and safusidenib, known for its efficacy against brain tumors. The company’s commitment is not just toward developing effective solutions but also to ensuring they positively transform the lives of patients.

In a rapidly evolving oncology landscape, Nuvation Bio's innovations aim to make significant strides and establish effective therapies that meet patients' critical needs. With their presence in New York, San Francisco, Boston, and Shanghai, Nuvation Bio is strategically positioned to address global oncology advancements.

As Nuvation Bio continues its journey, all interested parties are encouraged to participate in upcoming investor conferences. Engaging with the leadership during these discussions will provide valuable insights into the company's mission and innovations aimed at better patient outcomes in oncology.

For further details, visit Nuvation Bio's website or follow them on LinkedIn and X (@nuvationbioinc).